The ACTION VADs score for mortality can be calculated easily and offers risk stratification and prognostic information for pediatric VAD candidates. This is the first validated risk assessment tool for pediatric mechanical circulatory support.
Friday, April 12th 4:30–5:30 PM A Pediatric Heart Failure Registry: The Time for Action is Now Joseph Spinner, MD, et al.
ACTION @ ISHLT ’24: A Pediatric Heart Failure Registry: The Time for Action is Now Read More »
Happy New Year! We hope you enjoyed the Holiday Season and are energized for a new year! We wrapped 2023 with the launch of several exciting projects, such as the HeartMate 3TM Discharge Bundle and Heart Healthy Video Series, we continued access to the Berlin Heart Active Driver under the extended trial, and we published new ACTION research. Looking ahead this year we have been meeting individually with all ACTION sites to ensure successful engagement in ACTION and highlight membership benefits for each center. We are excited to expand quality improvement, education, research, and best practice initiatives across the network, as well as engage with Global centers and increase advocacy efforts in the pediatric heart failure space. Reach out with any new ideas for the year ahead. Thank you for your continued efforts!
The Pulse — January 2024 Read More »
Abstract Adult patients on left ventricular assist device (LVAD) support have increased morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There are no reported clinical data
COVID 19 infection in children causes a hyper-inflammatory syndrome referred to as multisystem inflammatory syndrome in children (MIS-C). This ACTION publication, published June 2, 2021 in Pediatric Cardiology, provides a
MIS-C Associated with COVID-19 Anti-thrombosis Guideline of Care for Children Read More »
ACTION defines and collects pediatric heart failure metrics to implement quality improvement initiatives. This study sought to describe medication use at the time of discharge for children admitted with acute
Establishing Baseline Metrics of Heart Failure Medication Use in Children Read More »
The Jarvik 2015 VAD, the first and currently only continuous-flow VAD specifically designed for small children, is being assessed in the Pump for Kids, Infants, and Neonates (PumpKIN) trial. Inclusion
“Compassionate” Cases of the Jarvik 2015 VAD Read More »
"*" indicates required fields
Copyright © 2024 Advanced Cardiac Therapies Improving Outcomes Network
